It's about follow through. OncBiomune follows through and builds confidence ("you build it, they will come") then they'll be able to get deals that don't trip this down to 0. I'm giving them till the end of the year before I scratch them off my list.
I think right now they need to prove the product line and show revenue coming in. I don't see nor can I project guidance for the moment. We'll need to see earnings. And get the trial rolling in the US.
News 
Market Data 
Discover 
